Multiple Myeloma

The AJMC^® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.

Latest News

July 1st 2025

Lower Tregs Linked With Survival in Multiple Myeloma

By Jared Kaltwasser

June 28th 2025

Highlighting Disparities in Myeloma Outcomes, the Impacts of Comorbidities

By Kimberly Rath, PharmD

June 19th 2025

Value-Based Care Calls for Putting Novel Therapies Closer to Patients

By Mary Caffrey

June 11th 2025

Stem Cell Transplant Remains Cost-Effective Option for MM: Mansi Shah, MD

By Laura Joszt, MA
Hayden E. Klein

June 7th 2025

Auto-SCT Superior to Allo-SCT in Relapsed Myeloma After First-Line Auto-SCT

By Jared Kaltwasser

Experts Weigh in on Multiple Myeloma

Explore the expanding role of bispecific antibody therapies and strategies for managing cytokine release syndrome and infection risks. Dive into real-world data on teclistamab and talquetamab, and uncover new approaches to optimize patient outcomes.

Video Interviews

June 30th 2025

Why a Patient With Multiple Myeloma Might Decline Stem Cell Transplant: Mansi Shah, MD

June 27th 2025

How Transplant, CAR T, and Bispecifics Fit Into Myeloma Care: Mansi Shah, MD

June 27th 2025

Balancing Timing of ASCT: Insights on Delayed Transplantation and Long-Term Treatment Outcomes

June 27th 2025

Tailoring Maintenance Therapy by Patient Risk: Lenalidomide Alone vs Combination Approaches

June 25th 2025

Self-Administered Subcutaneous Isatuximab May Ease Multiple Myeloma Treatment Burden: Xavier Leleu, MD, PhD

June 25th 2025

Trial Supports Subcutaneous Isatuximab as Effective Alternative to IV Version: Xavier Leleu, MD, PhD

June 25th 2025

Quality of Life Disparities Persist in R/R Multiple Myeloma Despite Universal Health Care: Francesco Sparano, MSc

June 25th 2025

Long-Term Data Support Cilta-Cel Use in R/R Multiple Myeloma: Sundar Jagannath, MBBS

June 20th 2025

The Role of MRD Status in Post-ASCT Treatment Decisions and Clinical Integration

June 20th 2025

Evaluating First-Line Treatment Options: Quadruplet vs Triplet Regimens and NCCN Guidelines

Continuing Medical Education

July 4th 2025

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology

July 4th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 4th 2025

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.5 Credit / Hematologic Cancer, Oncology

July 4th 2025

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.0 Credit / Oncology, Hematology, Hematologic Cancer

July 4th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

July 4th 2025

Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens

1.5 Credits / Hematologic Cancer, Hematology, Oncology

More News

Surbhi Sidana, MD, MBBS, Stanford University

June 19th 2025

CARTITUDE-4 Data Solidify Cilta-cel’s Role in RRMM: Surbhi Sidana, MD, MBBS

Maggie L. Shaw Surbhi Sidana, MD, MBBS

Surbhi Sidana, MD, MBBS, director of the Myeloma Disease Focused Group at Stanford University, provides a reintroduction to CARTITUDE-4 and insight on how this phase 3 investigation builds on previous findings of CAR T vs standard-of-care findings in relapsed/refractory multiple myeloma (RRMM)

Saad Z. Usmani, MD, MBA, FACP, FASCO, Memorial Sloan Kettering Cancer Center

June 18th 2025

DVRd vs VRd in Transplant-Ineligible Myeloma: Insights From Saad Z. Usmani, MD, MBA

Maggie L. Shaw Saad Z. Usmani, MD, MBA, FACP, FASCO

CEPHEUS trial lead investigator Saad Z. Usmani, MD, MBA, FACP, FASCO, explains how the trial both builds on current knowledge of newly diagnosed multiple myeloma and how transplant-ineligible status may affect therapeutic decision-making.

4 experts in this video

June 13th 2025

Treatment Approaches and Goals: Transplant-Eligible vs. Transplant-Ineligible Patients

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Ryan Haumschild, PharmD, MS, MBA Faith Davies, MD Shachar Peles, MD Sagar Lonial MD, FACP

Panelists discuss how treatment strategies differ between transplant-eligible and transplant-ineligible multiple myeloma patients, with transplant eligibility determined by functional status rather than age alone, and how quadruple therapy regimens are increasingly used for transplant-eligible patients to achieve deep, durable responses.

4 experts in this video

June 13th 2025

The Role of ASCT in Frontline Myeloma: Comparative Risks and Benefits with Other Standard Treatment Approaches

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA Ryan Haumschild, PharmD, MS, MBA Faith Davies, MD Shachar Peles, MD Sagar Lonial MD, FACP

Panelists discuss how autologous stem cell transplant remains essential in frontline multiple myeloma management despite improved quadruple therapy outcomes, emphasizing that current evidence still supports transplantation for eligible patients rather than deferring it.

May 19th 2025

Translating Best Practices and Ensuring Equitable Care as the Treatment Landscape Evolves

Laura Joszt, MA

AJMC Q&A with Harsh Parmar, MD | Background image credit: ipopba - stock.adobe.com

May 17th 2025

The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

Laura Joszt, MA Harsh Parmar, MD

Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.

Pieter Sonneveld, MD, PhD

May 15th 2025

Benefits of Continuing Subcutaneous Daratumumab After Initial Quad Therapy: Pieter Sonneveld, MD, PhD

Pieter Sonneveld, MD, PhD Rose McNulty Mary Caffrey

Pieter Sonneveld, MD, PhD, professor of hematology and chair of the Erasmus MC Cancer Institute in Rotterdam, Netherlands, discussed the continued use of subcutaneous daratumumab following initial treatment, as well as the changing landscape of multiple myeloma treatment.

Pieter Sonneveld, MD, PhD

May 5th 2025

"Exceptionally Long" PFS Projected With Daratumumab Quadruplet for Multiple Myeloma: Pieter Sonneveld, MD, PhD

Pieter Sonneveld, MD, PhD Mary Caffrey Rose McNulty

Pieter Sonneveld, MD, PhD, chair of the Erasmus MC Cancer Institute, discussed the findings of a study modeling long-term progression-free survival (PFS) in patients with multiple myeloma (MM) treated with a daratumumab quadruplet regimen.

Ajai Chari, MD

May 1st 2025

Considerations for Real-World MM Treatment: Ajai Chari, MD

Kyle Munz Ajai Chari, MD

Because clinical trials do not mimic the real-world application of multiple myeloma treatments, Ajai Chari, MD, discussed the variety of patient factors clinicians should consider in their practice.

Tailored approaches help patients with MM find the regimen that works best for them, which improves quality of life and outcomes | image credit: Dzmitry - stock.adobe.com

April 25th 2025

Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

Kyle Munz Ajai Chari, MD

When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.

Health equity concept | image credit: VectorMine - stock.adobe.com

April 7th 2025

Advancing MM Care Through Innovation and Equity: Ajai Chari, MD

Kyle Munz Ajai Chari, MD

Addressing the accessibility and high costs of chimeric antibody receptor (CAR) T-cell and bispecific therapies is crucial for maximizing their impact in multiple myeloma (MM).

Targeting GPRC5D Holds Promise in Multiple Myeloma

April 3rd 2025

Targeting GPRC5D Holds Promise in Multiple Myeloma

Jared Kaltwasser

Several studies have been conducted, but questions remain about where such therapies will fit into multiple myeloma treatment strategies.

Patient and doctor discussing symptoms. | Image credit: Intelligent Horizons - stock.adobe.com.jpeg

April 3rd 2025

PROs Associated With Survival, AEs in Multiple Myeloma

Jared Kaltwasser

The study highlights the importance of including patient self-assessment—and not just clinician assessment—when planning treatment in multiple myeloma.

Ajai Chari, MD

March 27th 2025

Optimizing Patient Selection for CAR T, Bispecifics Mitigates Adverse Events in High-Risk MM

Kyle Munz Ajai Chari, MD

For higher-risk multiple myeloma (MM), successful patient selection and monitoring strategies are vital for the management of adverse events and the disease itself.

Ajai Chari, MD

March 25th 2025

Making Bispecific Therapies Work in Community Settings

Kyle Munz Ajai Chari, MD

Ajai Chari, MD, stresses the importance of making bispecific therapies more accessible at the community level to improve outcomes in multiple myeloma.

Screenshot of an interview with Ajai Chari, MD

March 21st 2025

Streamlining "Brain-to-Vein" Time, Patient Selection, Imperative for Implementing CAR T for MM

Kyle Munz Ajai Chari, MD

Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.

Patients with multiple myeloma who did not complete a distress screener were also less likely to receive autologous stem cell transplants. | Image credit: LIghtfieldStudios - stock.adobe.com

March 20th 2025

Disparities in Multiple Myeloma Distress Screenings May Point to Care Gaps

Jared Kaltwasser

Patients who did not complete a distress screener were also less likely to receive autologous stem cell transplants.

Sabarish Ayyappan, MD

February 27th 2025

Cost-Effectiveness Strategies Vital for Streamlining Care in Hematologic Malignancies

Kyle Munz Sabarish Ayyappan, MD

More cost-effectiveness studies evaluating bispecific antibody or chimeric antigen receptor T-cell therapies are necessary for enhancing care in myeloma and lymphoma.

Sabarish Ayyappan, MD

February 24th 2025

Optimizing Approaches to CAR T, Bispecific Therapies in Myeloma and Lymphoma

Kyle Munz Sabarish Ayyappan, MD

Therapy timing, patient factors, and emerging combination interventions are guiding treatment decisions in multiple myeloma and lymphoma.

Current practices for IV isatuximab administration takes over an hour | image credit: NAMPIX - stock.adobe.com

February 13th 2025

Rapid IV Isatuximab Could Shift Care Practices in MM

Reducing intravenous (IV) isatuximab delivery from 75 minutes to 30 minutes could provide a wealth of benefits to patients with multiple myeloma (MM) and health care systems alike.

cell abnormalities, multiple myeloma | image credit: LASZLO - stock.adobe.com

February 7th 2025

Prolonged Survival in MM: Insights From the Largest Ongoing US Registry

The Connect MM Registry is the longest-running and largest registry in the US, providing invaluable prognostic insights into various patient and disease characteristics.

Optimizing Care Models for Bispecific Antibodies: Strategies for Cost-Effective Delivery

January 28th 2025

Optimizing Care Models for Bispecific Antibodies: Strategies for Cost-Effective Delivery

Jeffrey V. Matous, MD

Jeffrey V. Matous, MD, discusses how best practices in transitioning care between academic and community centers can enhance patient outcomes when receiving bispecific antibodies, and the critical role managed care organizations play in facilitating cost-effective integration of these therapies into community settings through optimized partnerships.

Streamlining Transitions Between Academic and Community Centers

January 28th 2025

Streamlining Transitions Between Academic and Community Centers

Jeffrey V. Matous, MD

Jeffrey V. Matous, MD, discusses how telehealth and remote monitoring can enhance the safe administration of bispecific antibody therapies in community settings, especially for rural or underserved populations, while emphasizing the importance of communication and collaboration between academic and community practices to improve delivery and coordination of care.

Leveraging Telehealth and Collaboration for Rural and Community Care Expansion

January 28th 2025

Leveraging Telehealth and Collaboration for Rural and Community Care Expansion

Jeffrey V. Matous, MD

Jeffrey V. Matous, MD, discusses how primary barriers to the widespread use of bispecific antibody therapies in community practices can be addressed through innovative care models, while reflecting on key insights from ASH 2024 abstracts that could guide broader adoption of these therapies in community settings.

Kirollos Hanna, PharmD

January 25th 2025

An Argument for Outpatient Bispecific Antibody Delivery: Dr Kirollos Hanna

Kyle Munz Kirollos Hanna, PharmD

Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.

Robert Rifkin, MD | Image credit: Rocky Mountain Cancer Centers

January 22nd 2025

Study of Prophylactic Tocilizumab May Soon Add Talquetamab Arm

Luke Halpern Laura Joszt, MA

Infection risk concept; floating bacterial particles | image credit: ChaoticMind - stock.adobe.com

January 21st 2025

High Infection Risk in MM: Insights From the Preimmunotherapy Era

Infection risk remains a prominent clinical concern for patients with multiple myeloma (MM), even with the advent of modern, novel therapies.

Expanding Bispecific Therapies to Community Settings: Challenges and Innovations

January 13th 2025

Expanding Bispecific Therapies to Community Settings: Challenges and Innovations

Amrita Krishnan, MD

Amrita Krishnan, MD, discusses how an ASH 2024 abstract from Sylvester Comprehensive Cancer Center suggests the potential of tocilizumab prophylaxis to mitigate cytokine release syndrome (CRS) in patients treated with bispecific therapies for multiple myeloma, and shares her approach to managing unique toxicities such as nail changes, skin reactions, and oral complications in patients receiving talquetamab.

Proactive CRS Management: The Role of Tocilizumab and Beyond

January 13th 2025

Proactive CRS Management: The Role of Tocilizumab and Beyond

Amrita Krishnan, MD

Amrita Krishnan, MD, discusses how data from ASH 2024 highlight the critical role of intravenous immunoglobulin (IVIG) treatment in preventing infections in patients receiving teclistamab, shares her approach to incorporating IVIG into clinical practice, and outlines additional strategies for reducing infection risk and managing cytokine release syndrome (CRS) in patients on bispecific antibody therapies for multiple myeloma.

MRD status cannot be detected with a microscope and is achieved through bone marrow analysis | image credit: Arthur Constantine - stock.adobe.com

January 13th 2025

MRD Negativity: A "Robust" Predictor of Survival Outcomes in MM

This meta-analysis sheds more light on the beneficial impact of multiple melanoma (MM) treatments and the predictive value of minimal residual disease (MRD) status for patient prognoses.

1 2 3 4 5 6 7 8

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions